Summary Germline mutations in the LKB1 (STK11) gene (chromosome sub-band 19p13.3) cause characteristic hamartomas and pigmentation to develop in patients with Peutz-Jeghers syndrome. Peutz-Jeghers syndrome carries an overall risk of cancer that may be up to 20 times that of the general population and Peutz-Jeghers patients are at increased risk of benign and malignant ovarian tumours, particularly granulosa cell tumours. Loss of heterozygosity (allele loss, LOH) has been reported in about 50% of ovarian cancers on 19p13.3. LKB1 is therefore a candidate tumour suppressor gene for sporadic ovarian tumours. We found allele loss at the marker D19S886 (19p13.3) in 12 of 49 (24%) sporadic ovarian adenocarcinomas. Using SSCP analysis, we screened ten ovarian cancers with LOH, 35 other ovarian cancers and 12 granulosa cell tumours of the ovary for somatic mutations in LKB1. No variants were detected in any of the adenocarcinomas. Two mutations were detected in one of the granulosa cell tumours: a mis-sense mutation affecting the putative 'start' codon (ATG → ACG, M1T); and a silent change in exon 7 (CTT → CTA, leucine). Like BRCA1 and BRCA2, therefore, it appears that LKB1 mutations can cause ovarian tumours when present in the germline, but occur rarely in the soma. The allele loss on 19p13.3 in ovarian cancers almost certainly targets a different gene from LKB1.
Mendelian diseases which predispose to ovarian tumours include familial breast/ovarian cancer (resulting from germline BRCA1 and BRCA2 mutations), Gorlin syndrome (resulting from PTCH mutations), hereditary non-polyposis colon cancer (HNPCC, resulting from mismatch repair gene mutations) and Peutz-Jeghers syndrome (PJS, MIM175200). PJS is characterized by hamartomatous polyps of the gastrointestinal tract and other epithelia, and by freckling of the lips, buccal mucosa and other sites (Tomlinson and Houlston, 1997) . PJS patients have an increased risk of neoplasia of multiple sites. This risk may approach a 20-fold increase over the general population if all organs are considered, although the increased risk for any particular site is necessarily more modest (Murday and Slack, 1989) .
The gene for PJS has recently been shown to be a serine/ threonine kinase, known as LKB1 or STK11 (Genbank U63333), which maps to chromosome sub-band 19p13.3 (Hemminki et al, 1997 (Hemminki et al, , 1998 . This gene acts as a tumour suppressor in the hamartomatous polyps of PJS patients and probably also acts as a tumour suppressor in the other neoplasms that develop in PJS patients (Wang et al, 1999) . It is not clear whether these neoplasms develop from hamartomas, or whether the LKB1 locus plays a role in a different genetic pathway of tumour growth, although the former is more likely.
Peutz-Jeghers patients are at increased risk of a number of gynaecological neoplasms. These include benign and malignant ovarian lesions, especially granulosa cell tumours (GCTs), in addition to adenoma malignum of the cervix and endometrial adenocarcinoma. Ovarian adenocarinomas show a relatively high frequency of loss of heterozygosity (allele loss, LOH) on chromosome 19p13.3 (Sato et al, 1991; Osborne and Leech, 1994; Amfo et al, 1995; Pejovic, 1995) . LKB1 is therefore a good candidate for involvement in the pathogenesis of sporadic tumours of the ovary. We have analysed a set of sporadic adenocarcinomas of the ovary for allele loss on chromosome 19p13.3 and then screened these tumours and a set of ovarian granulosa cell tumours for mutations in the LKB1 gene.
METHODS
Using standard methods, DNA was extracted from 60 samples of unselected, fresh-frozen sporadic adenocarcinomas of the ovary and matched normal tissue or blood. After microdissection to enrich for tumour material, DNA was extracted from fixed, paraffin-embedded samples of 12 GCTs of the ovary using proteinase K digestion and the Qiagen tissue extraction kit. None of these cases had known clinical or familial features suggestive of PJS. Standard clinicopathological data (patient age, and tumour grade and stage) were available from hospital records.
For allele loss analysis at LKB1, the D19S886 microsatellite marker was used; this maps within 500 kb of LKB1 (http://wwwbio.llnl.gov/). About 50 ng of DNA from paired tumour/normal samples from the ovarian adenocarcinoma patients were amplified using the polymerase chain reaction (PCR) under standard conditions. The forward primer had previously been end-labelled with γ-32 ATP using 3U of T4 polynucleotide kinase. Radio-labelled products were electrophoresed through 6% denaturing polyacrylamide gels, dried and exposed to X-ray film for 24 h. Quantitation of PCR products from tumours and the corresponding constitutional DNA was achieved using the Molecular Dynamics phoshorimager and software. Allele loss was scored if the area under an allelic peak was reduced to < 50% of its original value (relative to the other allele), thus making allowance for the presence of contaminating stromal tissue or inflammatory infiltrate in some of the tumours.
Single-strand conformational polymorphism (SSCP) analysis was performed on the tumour samples as the method of mutation screening at LKB1. For the adenocarcinomas, published oligonucleotides and reaction conditions were used for exon-by-exon amplification of LKB1 in the PCR (Wang et al, 1998) . For the GCTs, new oligonucleotides were designed to produce shorter PCR target sequences which were more likely to amplify successfully from fixed archival material in the PCR (Table 1) . A PCR protocol of 94°C (3 min) × 1, 94°C (1 min)/Ta °C (1 min)/72°C (1 min) × 35, 72°C (5 min) × 1 was used for the GCTs, with the addition of 0.02% dimethyl sulphoxide (DMSO) and 0.1% bovine serum albumin (BSA) to the reaction where necessary. PCR products were heated to 90°C for 5 min and subjected to electrophoresis on an 8% acrylamide gel (37.5:1 acrylamide: bisacrylamide, 10% glycerol) under non-denaturing conditions at 20 mA for about 16 h. DNA was detected by silver-staining of gels using standard methods. For all tumours with possible mutations according to SSCP analysis, the appropriate exon was reamplified from genomic DNA in the PCR, and purified PCR products were sequenced in forward and reverse orientation using the ABI Ready Reaction Dye Terminator Cycle Sequencing kit and the 373 sequencer. All sequencing reactions were performed in duplicate and alongside samples with wild-type genotypes, and patient samples with known germline mutations in LKB1.
RESULTS AND DISCUSSION
Allele loss was found at D19S886 in 12 of 49 (24%) informative ovarian adenocarcinomas (out of the total of 60 studied). This is apparently a somewhat lower frequency of allele loss on 19p than found in some studies, but inspection of the data from these other studies shows that our results are in agreement if the previous analysis of multiple markers on 19p, the sample sizes used and the different tumour types studied are taken into account. Sato et al (1991) found allele loss at D19S20 (4 cM from D19S886) in five of 19 (26%) adenocarcinomas of the ovary (map data from GGT GTG TG  58  160  GA986  CCC TAG CAC GTG CCT ACC TC  GA951  GTG GCA CCC TCA AAA TCT CC  57  183  GA1134  TCC AGG CCG TTG GCA ATC TC  GA1071  ACC CGT TCG CGG CGG ACG  58  152  GA1223  AGT GTG CGT GTG GTG AGT GC  6  GA1659  TGA CTG ACC ACG CCT TTC TT  57  218  GA1877  CCC CCA ACC CTA CAT TTC TG  7  GA2412  CTC CTC GCC GGC TTC TCC TC  62  155  GA2567  CCC CAC CAC GCC CTG CTC TA  8  GA3439  GAC AGG CGC CAC TGC TTC TG  60  251  GA3690  GGA CAT CCT GGC CGA GTC AG  9  GE001  GTA AGT GCG TCC CCG TGG TG  59  337  GE338 GTG GCA TCC AGG CGT TGT CC ftp://cedar.genetics.soton.ac.uk/pub/chrom19/map). Osborne and Leech (1994) found allele loss at D19S177 (20 cM proximal to D19S886) in four of ten (40%) ovarian adenocarcinomas of the ovary. Amfo et al (1995) detected allele loss (in addition to one putative rearrangement) in two of nine (22%) adenocarcinomas at the INSR locus (23 cM proximal to D19S886). Our results do not differ significantly from any of these other studies (χ 2 test, details not shown). LKB1 therefore remained an excellent candidate gene for acting as a tumour suppressor in ovarian tumorigenesis. In a set of ten adenocarcinomas with LOH, in 35 other adenocarcinomas selected at random, and in 12 GCTs, a small number of variant bands suggestive of somatic mutations at LKB1 was detected on SSCP analysis. In all the carcinomas, these putative bandshifts were shown on sequencing to be intronic polymorphisms or other intronic variants with no predicted effect on mRNA or protein. A commonly observed biallelic polymorphism (C/G, heterozygosity 44% in a sample of 34 individuals) was found in intron 7 at the +8 splice donor site. This polymorphism is found at approximately equal allele frequencies (details not shown) in normal individuals, in PJS patients and in tumours, and it almost certainly has no effect on mRNA splicing; it may, however, be useful for future allele loss studies at the LKB1 locus. No LKB1 mutations were found in the adenocarcinomas. Two mutations were, however, detected in one of the granulosa cell tumours ( Figure 1 ): a mis-sense mutation affecting the putative 'start' codon (ATG → ACG, M1T); and a silent change in exon 7 (CTT → CTA, leucine). These variants were not present in the germline. Analysis of the sequence showed that this tumour did not exhibit allele loss at LKB1. No particular clinicopathological features distinguished this granulosa cell tumour from any of the others.
It is not clear whether or not the M1T mutation in one of the granulosa cell tumours has any pathogenic effect. Certainly, it occurs outside the kinase core (codons 50-337) in which most germline mutations have been found (Hemminki et al, 1998) . Although codon 1 provides the best candidate 'start' codon for LKB1 translation, there are several alternative 'start' codons just downstream (at codons 11, 18 and 22) which may allow near-normal function of the LKB1 protein. Codon 22, in particular, is flanked by sequences which suggest that it could function efficiently as an alternative initiator of translation. It is even possible that the methionine at codon 1 is not the usual 'start' site for LKB1. The M1T mutation has not, however, been observed as a variant in over 50 other PJS patients, tumours and normal individuals sequenced for exon 1 of LKB1.
SSCP only detects about 80% of mutations (Sheffield et al, 1993; Ravnik et al, 1994; Vidal and Moller, 1994) , and this figure may be somewhat lower for some types of point mutation. We have not excluded further possibilities for the involvement of LKB1 in ovarian tumorigenesis, such as gene silencing by promoter methylation, or hemi-or homozygous deletion of either locus (whether the entire gene or whole exons). Thus, it remains possible that mutations or transcriptional inactivation at LKB1 occur in a larger proportion of ovarian tumours than we have reported. It remains most likely, however, that -similar to that with the BRCA1 and BRCA2 genes in familial breast/ovarian cancer -inherited variation in LKB1 predisposes to ovarian tumours in PJS, but somatic mutations in the same gene are rarely important for the pathogenesis of sporadic tumours of this site. Occasional LKB1 mutations with pathogenic effects have been found in cancers of the colon, testis, lung and skin (Dong et al, 1998; Wanger et al, 1998; Rowan et al, 1999; Wang et al, 1999; Ylikorkala et al, 1999) .
Although somatic LKB1 mutations may be important in the pathogenesis of a minority of sporadic granulosa cell tumours, it is most likely that LKB1 is not mutated in ovarian adenocarcinomas and that the allele loss observed on chromosome 19p13.3 in these cancers targets a different locus from LKB1. Whether or not INSR is actually the gene involved, the combined data from previous work and our study suggest that allele loss on 19p13.3 in ovarian cancer targets a different locus from LKB1. Candidate genes in this region of chromosome 19p include basigin, CDC34, PTPRS, AMH, ICAM1, ICAM3 and CDKN2D.
